Arrien Pharmaceuticals is a technology driven biopharmaceutical company focused on discovery and development of innovative and effective drug candidates for the treatment of human cancers. The company currently has three drug candidates for oncology and two other programs in development for non-oncology indications.
ARN-6039 Phase 1 clinical trials completed agent initially licensed to Boston Pharmaceuticals in 2017 further licensed to Xenter, Inc.
ARN-3261 is a SIK2 inhibitor in development, competed its IND enabling studies, and Licensed to Greenfire Bio. Clinical Phase 1a/1b trial initiated in Q2 2021.